Immunotoxins: An update

Annual Review of Immunology

Volumn 14, Issue , 1996, Pages 49-71

  Thrush, Gerald R ^a   Lark, Laura R ^a   Clinchy, Birgitta C ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

AIDS; autoimmune disease; bone marrow transplantation; cancer; immunotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD22 ANTIGEN; CD5 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; CYTOKINE RECEPTOR; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOTOXIN; PLANT TOXIN; PREDNISONE; PSEUDOMONAS EXOTOXIN; RIBOSOME INACTIVATING PROTEIN; XOMAZYME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNITY; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DRUG THERAPY; GRAFT VERSUS HOST REACTION; HEMATURIA; HLA MATCHING; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA; MYALGIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; REVIEW; T CELL LYMPHOMA; THROMBOCYTOPENIA; VASCULAR DISEASE;

ANIMALS; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY, ACTIVE; IMMUNOTOXINS;

EID: 0029920448     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.14.1.49     Document Type: Review

References (12)

1. Thorpe PE, Ross WC. 1982. The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol. Rev. 62:119-58
2. Lord JM, Spooner RA, Hussain K, Roberts LM. 1988. Immunotoxins: properties, applications and current limitations. Adv. Drug Deliv. Rev. 2:297-318
3. Pietersz GA, Rowland A, Smyth MJ, McKenzie IFC. 1994. Chemoimmunoconjugates for the treatment of cancer. Adv. Immunol. 56:301-86
4. Ghetie V, Vitetta ES. 1994. Immunotoxins in the therapy of cancer: from bench to clinic. Pharmacol. Ther. 63(3):209-34
5. Pastan I, Chaudhary V, FitzGerald DJ. 1992. Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem. 61:331-54
6. Woodworth T, Nichols J. 1993. Recombinant fusion toxins - a new class of targeted biologic therapeutics. In Immunoconjugate Therapy of Hematologic Malignancies, ed. ST Rosen, TM Kuzel, pp. 145-60. Boston/Dordrecht/London: Kluwer Acad.
7. Yamaizumi M, Mekada E, Uchida T, Okada Y. 1978. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15:245-50
8. Eiklid K, Olsnes S, Pihl A. 1980. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp. Cell Res. 126:321-26
9. Pastan I, Willingham MC, FitzGerald DJP. 1986. Immunotoxins. Cell 47:641-48
10. Vitetta ES, Fulton RJ, May RD, Till M, Uhr JW. 1987. Redesigning nature's poisons to create anti-tumorreagents. Science 238:1098-104
11. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom TB, Murphy JR. 1987. Diphtheria toxin binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng. 1:493-98
12. Byers VS, Baldwin RW. 1992. Targeted kill: from umbrellas to monoclonal antibodies. J. Clin. Immunol. 12:391-405